Northfield Laboratories, Inc. (NASDAQ: NFLD), a leading developer of oxygen-carrying red blood cell substitute, is focused on addressing the need for the treatment of life-threatening blood loss when oxygen-carrying fluid is required and red blood cells are not available. The company’s PolyHeme product restores lost blood volume and hemoglobin levels and is able to be administered rapidly in massive amounts. For further information, visit the Company’s web site at www.northfieldlabs.com.
- 17 years ago
QualityStocks
Northfield Laboratories, Inc. (NASDAQ: NFLD)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – VolitionRx (NYSE American: VNRX) Prepares Reimbursement Submission for Nu.Q Cancer Assays in France
VolitionRx Ltd. (NYSE American: VNRX) (“Volition”), a multi-national epigenetics company, announced that it is preparing a reimbursement submission for its Nu.Q®…
-
QualityStocksNewsBreaks – Brand Engagement Network Inc. (NASDAQ: BNAI) Reports Warrant Exercises, Debt Conversion, and Public Warrants Update
Brand Engagement Network Inc. (NASDAQ: BNAI) announced on Wednesday that it generated approximately $1.46 million…
-
Soligenix (NASDAQ: SNGX) Positioning for Impact in Growing Rare-Disease Landscape
The World Health Organization’s recent recognition of rare diseases as a global health priority underscores…